Missouri 2025 Regular Session

Missouri Senate Bill SJR23 Latest Draft

Bill / Introduced Version Filed 12/05/2024

                             
FIRST REGULAR SESSION 
SENATE JOINT RESOLUTION NO. 23 
103RD GENERAL ASSEMBLY  
INTRODUCED BY SENATOR SCHROER. 
1204S.01I 	KRISTINA MARTIN, Secretary  
JOINT RESOLUTION 
Submitting to the qualified voters of Missouri, an amendment to article I of the Constitution of 
Missouri, by adding thereto one new section relating to reproductive health care. 
 
Be it resolved by the Senate, the House of Representatives concurring therein: 
     That at the next general election to be held in the 1 
state of Missouri, on Tuesday next following the first Monday 2 
in November, 2026, or at a special election to be called by 3 
the governor for that purpose, there is he reby submitted to 4 
the qualified voters of this state, for adoption or 5 
rejection, the following amendment to article I of the 6 
Constitution of the state of Missouri:7 
     Section A.  Article I, Constitution of Missouri, is amended 1 
by adding thereto one new section, to be known as section 36(a), 2 
to read as follows:3 
     Section 36(a).  1.  The provisions of this section 1 
shall be known and may be cited as the "Reproductive Health 2 
Care Protection Act". 3 
     2.  Notwithstanding any provision of sectio n 36 of  4 
article I of this Constitution to the contrary, the right to 5 
reproductive freedom shall not be construed to include: 6 
     (1)  The performance of gender transition surgeries or 7 
the prescription or administration of cross -sex hormones or  8 
puberty-blocking drugs for the purpose of gender transition; 9 
and 10   SJR 23 	2 
     (2)  The payment for the performance or inducement, or 11 
assistance with the performance or inducement, of abortions 12 
by taxpayers, except in cases of medical emergencies. 13 
     3.  Notwithstanding any provision of section 36 of 14 
article I of this Constitution to the contrary, the right to 15 
reproductive freedom shall not be construed to exempt any 16 
person, firm, or corporation from civil liability for 17 
medical malpractice, negligence, or wrongfu l death. 18 
     4.  The general assembly shall have the authority to 19 
enact laws to carry out the provisions of this section. 20 
     5.  As used in this section, the following terms mean: 21 
     (1)  "Cross-sex hormones", testosterone, estrogen, or 22 
other androgens given to an individual in amounts that are 23 
greater or more potent than would normally occur naturally 24 
in a healthy individual of the same age and sex, but shall 25 
not include hormones used to treat individuals born with a 26 
medically-verifiable disorder of sex development or the 27 
treatment of any infection, injury, disease, or disorder 28 
unrelated to the purpose of gender transition; 29 
     (2)  "Gender transition surgery", a surgical procedure 30 
performed for the purpose of assisting an individual with 31 
identifying with and living as a gender different from his 32 
or her biological sex, but shall not include surgical 33 
procedures for individuals born with a medically -verifiable  34 
disorder of sex development or the treatment of any 35 
infection, injury, disease, o r disorder unrelated to the 36 
purpose of gender transition; 37 
     (3)  "Medical emergency", a condition which, based on 38 
reasonable medical judgment, so complicates the medical 39 
condition of a pregnant woman as to necessitate the 40 
immediate abortion of her p regnancy to avert the death of 41 
the pregnant woman or for which a delay will create a 42   SJR 23 	3 
serious risk of substantial and irreversible physical 43 
impairment of a major bodily function of the pregnant woman; 44 
     (4)  "Puberty-blocking drugs", gonadotropin -releasing  45 
hormone analogues or other synthetic drugs used to stop 46 
luteinizing hormone secretion and follicle stimulating 47 
hormone secretion, synthetic antiandrogen drugs to block the 48 
androgen receptor, or any other drug used to delay or 49 
suppress pubertal development in children for the purpose of 50 
assisting an individual with a gender transition, but shall 51 
not include drugs used to treat individuals born with a 52 
medically-verifiable disorder of sex development or the 53 
treatment of any infection, injury, di sease, or disorder 54 
unrelated to the purpose of gender transition. 55 
